Latest close: a new 52-week lowSep 8, 2026what changed →
On our screens:Cheap stocks by free cash flow yield
The financials
Collegium Pharmaceutical, Inc. by the numbers
Collegium Pharmaceutical, Inc. (COLL) reported revenue of $194M in Q1 2026 (quarter ended Mar 31, 2026), up 8.9% from the same quarter a year earlier. That came with a gross margin of 61% and net income of $14M (7.5% of revenue). For the full year FY2025, revenue was $781M (+24% year on year) and net income $63M. Its largest product in Jun 2026 was Belbuca at $58M, 29% of the disclosed total, just ahead of Jornay Pm at 23%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $194M | $178M | +8.9% |
| Gross profit | $117M | $97M | +20% |
| Operating income | $31M | $22M | +42% |
| Net income | $14M | $2.4M | +500% |
| Diluted EPS | $0.40 | $0.07 | +471% |
| Product | Revenue | Share |
|---|---|---|
| Belbuca | $58M | 29% |
| Jornay Pm | $46M | 23% |
| Xtampza ER | $45M | 23% |
| Nucynta ER | $16M | 7.9% |
| Nucynta IR | $14M | 7.2% |
| Azstarys | $13M | 6.5% |
| Symproic | $3.0M | 1.5% |
| Nucynta ERAG | $2.8M | 1.4% |
| Nucynta IRAG | $2.4M | 1.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $199.9M (+3.3%)
Jornay Pm grew +41% year on yearNucynta IR -46% year on year
Segment Latestquarter on quarteryear on year
- Belbuca$57.7M$57.7MQoQ +9.5%year on year +9.6%+9.5%+9.6%
- Jornay Pm$46.1M$46.1MQoQ +18%year on year +41%+18%+41%
- Xtampza ER$45.0M$45.0MQoQ -11%year on year -14%-11%-14%
- Nucynta ER$15.7M$15.7MQoQ -14%year on year -21%-14%-21%
- Nucynta IR$14.4M$14.4MQoQ -45%year on year -46%-45%-46%
- Azstarys$12.9M$12.9MQoQ -year on year ---
- Symproic$3.0M$3.0MQoQ -28%year on year -19%-28%-19%
- Nucynta ERAG$2.8M$2.8MQoQ +92%year on year -+92%-
- Nucynta IRAG$2.4M$2.4MQoQ +88%year on year -+88%-
Drug Manufacturers - Specialty & Generic
Ranks #16 of 29 by Smart Score